Biotech in Flanders - A Stunning Story ​ 

A new book reveals the secrets behind the success of the Flemish life sciences biotech industry

Ghent/Leuven, 13 November 2023 Flanders, the northern region of Belgium, is home to one of the most vibrant and innovative life sciences and biotech ecosystems in the world. Over the past 40 years, Flemish researchers and pioneers have made discoveries that today benefit over two million patients every year, and are used daily in agriculture, research labs and medical cabinets. How did this small region become a global leader in life sciences and biotechnology? What are the key factors that contributed to this remarkable development? Who are the pioneers and visionaries that shaped its history during the past 40 years? And what’s ahead for this thriving ecosystem? 

These are some of the questions that are answered in a new book, Biotech in Flanders - A Stunning Story, written by Jo Bury, Johan Cardoen and Dirk Reyn, three experts who have been closely involved in the Flemish biotech sector for decades. The book tells the fascinating story of how Flanders transformed itself into a world recognized biotech powerhouse, thanks to a fruitful cross-fertilization between high quality healthcare, excellent scientific research, daring entrepreneurship and industry collaboration, risky financing and a supportive government. 

Biotech in Flanders - A Stunning Story is a must-read for anyone interested in biotechnology, entrepreneurship, and regional biotech ecosystem development. 

The book is based upon more than 40 interviews, including many of the iconic figures of the Flemish biotech story who share their insights and experiences on the challenges and opportunities of almost half a century of biotech innovation. 

The book provides an overview of the current state and future prospects of the Flemish biotech industry, which counts several hundred of companies and employs some sixty thousand people, both in direct and supportingjobs. ​ 

Biotech in Flanders A Stunning Story offers an inspiring guide for those who want to gain insight into the ins and outs of an innovative and research-driven sector, working day after day on products that continually make the lives of millions of people safer, healthier and more sustainable. 

It is a stunning story, without question. It is also a tribute to the vision and passion of the people who made Flanders Biotech Valley a reality.

Published by Witsand Uitgevers (www.witsand.be), the book was created in collaboration with VIB (www.vib.be), flanders.bio (www.flanders.bio) and Flanders Investment & Trade (corporate.flandersinvestmentandtrade.com). It is available in Dutch and English.

Book available on www.biotechinflanders.com 

"Biotech in Flanders: A stunning story" now available for purchase

Joran Lauwers

Joran Lauwers

Press Contact, VIB

Share

Latest stories

Website preview
New research brings personalized treatment for Parkinson’s disease a step closer
Leuven, 5 May 2026 – A new study led by researchers from VIB and KU Leuven shows that Parkinson’s disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using an machine-learning-driven analysis, the team identified two main groups and five subgroups of the disease, marking an important step toward more personalized therapies. The findings were recently published in Nature Communications.
press.vib.be
Website preview
New lung cancer model reveals how tumor location shapes the immune response
Brussels, 27 April 2026 – Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside lung tumors. By combining a patient-relevant mouse model with single-cell technologies, the team provides one of the most comprehensive immune maps to date of lung adenocarcinoma, which is the most common subtype of lung cancer. Their work appears in Nature Communications.
press.vib.be
Website preview
Molecular keyhole sheds light on pain and epilepsy
Leuven, 21 April 2026 – Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular ’keyhole’, in the TRPM3 ion channel, a crucial sensor in pain signaling. TRPM3 is also linked to rare neurodevelopmental disorders and epilepsy. In a recent study published in Nature Communications, the researchers found that even the slightest change in this keyhole can radically switch the channel’s behavior, explaining how certain mutations can flip the effects of drugs.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be